AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.23 |
Market Cap | 545.55M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.34 |
PE Ratio (ttm) | -3.16 |
Forward PE | n/a |
Analyst | Buy |
Ask | 4.25 |
Volume | 746,853 |
Avg. Volume (20D) | 4,907,577 |
Open | 4.20 |
Previous Close | 4.12 |
Day's Range | 4.03 - 4.24 |
52-Week Range | 2.48 - 9.97 |
Beta | undefined |
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without i...
Analyst Forecast
According to 8 analyst ratings, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 230.19% from the latest price.
Next Earnings Release
Analysts project revenue of $420.00K, reflecting a n/a YoY growth and earnings per share of -0.26, making a 8.33% increase YoY.